Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Composite Lymphoma × ALX148 × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasm Metastasis 1 Lymphoma, Mantle-Cell 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 HER2-expressing Cancers 1 Composite Lymphoma 1 Breast Neoplasms 1

Interventions

Rituximab 1 Lenalidomide 1 CT-P10 1 ALX148 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05025800 2025-10-09

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Composite Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡